Jan Willem van der Laan

Summary

Affiliation: National Institute for Public Health and the Environment
Country: The Netherlands

Publications

  1. ncbi Immune function testing of human pharmaceuticals: regulatory overshoot?
    Jan Willem van der Laan
    Expert Opin Drug Saf 4:1-5. 2005
  2. ncbi Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague
    Jan Willem van der Laan
    National Institute for Public Health and the Environment, Centre for Biological Medicines and Medical Technology, The Netherlands
    Expert Rev Vaccines 4:15-8. 2005
  3. ncbi Animal models in influenza vaccine testing
    Jan Willem van der Laan
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Expert Rev Vaccines 7:783-93. 2008
  4. ncbi Current status and use of short/medium-term models for assessment of carcinogenicity of human pharmaceuticals: regulatory perspectives
    J W van der Laan
    Preclinical Assessment Group of the Medicines Evaluation Board in The Netherlands, National Institute of Public Health and the Environment, 3720 BA, Bilthoven, The Netherlands
    Toxicol Lett 112:567-72. 2000
  5. ncbi Current status and burning issues in immunotoxicity testing of drugs
    Jan Willem van der Laan
    Centre for Biological Medicines and Medical Technology, National Institute of Public Health and the Environment, P O Box 1, NL 3720 BA Bilthoven, The Netherlands
    Toxicol Appl Pharmacol 207:435-40. 2005
  6. ncbi Alternatives models in carcinogenicity testing--a European perspective
    JanWillem van der Laan
    Laboratory for Medicines and Medical Devices, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Toxicol Pathol 30:157-9. 2002
  7. ncbi Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products
    Jan Willem van der Laan
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
    J Pharmacol Toxicol Methods 62:184-95. 2010
  8. ncbi Statins accelerate the onset of collagen type II-induced arthritis in mice
    Rob J Vandebriel
    Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Arthritis Res Ther 14:R90. 2012
  9. ncbi Testing therapeutic potency of anticancer drugs in animal studies: a commentary
    Willem Den Otter
    Preclinical Assessment Group of the Medicines Evaluation Board in The Netherlands, Laboratory for Medicines and Medical Devices, 3720 BA Bilthoven, The Netherlands
    Regul Toxicol Pharmacol 35:266-72. 2002
  10. ncbi An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies
    Nele Pentsuk
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
    Birth Defects Res B Dev Reprod Toxicol 86:328-44. 2009

Collaborators

Detail Information

Publications12

  1. ncbi Immune function testing of human pharmaceuticals: regulatory overshoot?
    Jan Willem van der Laan
    Expert Opin Drug Saf 4:1-5. 2005
    ..g., lymphocytes, macrophages). Criteria to differentiate among compounds in this category have yet to be ascertained...
  2. ncbi Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague
    Jan Willem van der Laan
    National Institute for Public Health and the Environment, Centre for Biological Medicines and Medical Technology, The Netherlands
    Expert Rev Vaccines 4:15-8. 2005
  3. ncbi Animal models in influenza vaccine testing
    Jan Willem van der Laan
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Expert Rev Vaccines 7:783-93. 2008
    ..The main animals used for testing vaccines destined for human use are laboratory mice and ferrets and, to a lesser extent, macaques. We will focus particularly on these species...
  4. ncbi Current status and use of short/medium-term models for assessment of carcinogenicity of human pharmaceuticals: regulatory perspectives
    J W van der Laan
    Preclinical Assessment Group of the Medicines Evaluation Board in The Netherlands, National Institute of Public Health and the Environment, 3720 BA, Bilthoven, The Netherlands
    Toxicol Lett 112:567-72. 2000
    ..At present there is insufficient information to predict or offer guidance on which of the models may be the most suitable. New models are not useful to test the carcinogenic potential of biotechnological products...
  5. ncbi Current status and burning issues in immunotoxicity testing of drugs
    Jan Willem van der Laan
    Centre for Biological Medicines and Medical Technology, National Institute of Public Health and the Environment, P O Box 1, NL 3720 BA Bilthoven, The Netherlands
    Toxicol Appl Pharmacol 207:435-40. 2005
    ..The Expert Working Group of the ICH has decided to choose a cause-for-concern approach to immunotoxicity rather than a routine-screening approach. The causes for concern are to be defined during ICH negotiations...
  6. ncbi Alternatives models in carcinogenicity testing--a European perspective
    JanWillem van der Laan
    Laboratory for Medicines and Medical Devices, National Institute of Public Health and the Environment, Bilthoven, The Netherlands
    Toxicol Pathol 30:157-9. 2002
    ....
  7. ncbi Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products
    Jan Willem van der Laan
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
    J Pharmacol Toxicol Methods 62:184-95. 2010
    ..For most purposes, minipigs may be considered an acceptable choice as non-rodent species, provided adequate justification for this choice is made...
  8. ncbi Statins accelerate the onset of collagen type II-induced arthritis in mice
    Rob J Vandebriel
    Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Arthritis Res Ther 14:R90. 2012
    ..Our objective was to investigate whether a causal relationship could be established for this finding...
  9. ncbi Testing therapeutic potency of anticancer drugs in animal studies: a commentary
    Willem Den Otter
    Preclinical Assessment Group of the Medicines Evaluation Board in The Netherlands, Laboratory for Medicines and Medical Devices, 3720 BA Bilthoven, The Netherlands
    Regul Toxicol Pharmacol 35:266-72. 2002
    ..This stimulates considerations on how to organize and how to evaluate these tests. In this article we describe our considerations regarding these items based on our experience with applications in The Netherlands since 1993...
  10. ncbi An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies
    Nele Pentsuk
    Section on Safety of Medicines and Teratology, Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
    Birth Defects Res B Dev Reprod Toxicol 86:328-44. 2009
    ....
  11. ncbi New adjuvanted vaccines in pregnancy: what is known about their safety?
    Carla Herberts
    Centre for Biological Medicines and Medical Technology, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The Netherlands
    Expert Rev Vaccines 9:1411-22. 2010
    ..Here, we review the available information and discuss how vaccination may interfere with pregnancy, fetal development and pregnancy outcomes...
  12. ncbi The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI
    James Macdonald
    Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Toxicol Sci 77:188-94. 2004
    ..Based on the outcome of the workshop, various studies are proposed to provide data to improve the utility of currently available assays for cancer hazard identification and risk assessment purposes...